The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I do not believe they are behind schedule as they would have been required to amake an announcement. As far as we know all components had been manufactured according to previous RNS, so to me it would be safe to assume it was just a question of transportation to Daresbury. Daresbury is the intallation and testing site and also I understand first treatment will be undertaken there in Q4 2020. If I have mised an announcement please let me know?
Great announcement now two treatment rooms in Harley Street and shows significant confidence in the LIGHT system.
Over 50 million shares traded today already, has anyone any idea what the news is? Clearly some took profits earlier when the price hit 19c and no confirmed news. The chart is looking very healthy, if there really is some good news could easily be back in the 20-30c range soon.
Clearly something has sparked the buying which is moving the stock significantly when the rest of the market goes down. This is not being handled well by the company if there is news it should be released asap. If all pending news outcomes are positive (EU,HK,&FDA) I will be very pleased as I have held for the past 10 years + Time will tell but to achieve circa $1 would be probably achievable if and only if there are positive outcomes across all pending news expectations.
Interesting share action today, any ideas as to the reason? I believe we are awaiting EU permissions, potential FDA and launches in HK / Macau? Are there any rumors? Cheers
Personally I am not expecting to hear until well into 2020 that the LIGHT sysytem is fully operational. In the companies timeline they were targeting all components being delivered by the end of 2019 to the Daresbury Lab including the Patient Positioning equipment. Until they are delivered they will obviously need to be set up and calibrated which I asssume is the reported integration and testing phase as described in the half year report. Treating of 1st patients is is still in the plan for 2020. The recent fund raising has also been ear marked for progressing verification and validation activity in order to obtain regulatory approval, so I guess there is much work to do.
Thanks I will probably sell out soon then, I appreciate the post. I think I will await any potential announcement this month and then sell in January. I was going to say can not get much worse but I guess zero at this stage is a strong ppssibility, Good luck all
Do you know what the next steps are and process / timescales for a decision are likely to be from the EMA? Seems to me to be potentially good news. In addition I beleive we are awaiting hopefully stage II validation in the USA this month. All is quiet on the CBD developments which I guess may or may not be progressing. It is also about time we had a status update from the company on all developments and looking at previous years I would hope this month. Overall it seems the share price has nothing baked in assuming on all fronts diaster, hope I am wrong as I have been a holder of PLE before RPG took over 10 years!
Actually it was released 2 weeks ago I just received it via email...maybe others also missed it
Well worth listening to, released 25th November 2019
https://vimeo.com/372826794
Q&A with Dr Martin Hall, Head of Life Sciences at Hardman & Co joins ************* "AVO is uniquely positioned"
I like the valuation at 8.07 minutes at £2.29p valuation.
No component delivery is delayed. Everything is well on track. As the chairman commented at the end of his Half Year Report "I look forward to updating the market with more positive news very soon". Do you really think he is making it up?? DYOR
Correction typo NPV is £239 per share
https://www.hardmanandco.com/research/corporate-research/nearing-the-end-goal/?dm_i=49CL,MPUM,4BETET,2O4YY,1
Very encouraging report and looks like the company is also planning following assembly of the system to treat a small cohort of patients at Daresbury next year! NPV at £293 per share shows a big disconnect with the current share price & Target Price from Goetzpartners of £1.55. Pleased to see everything is on track!
Unfortunately Solow it is the nature of any new start company...in 6 years the company has had some new major shareholders, new investors, new CEO plus plus Excecutive team and advisors that are at the top of their profession. Looking back is not really relevant now. What we do know is that there is a working system generating 52 Mev in Geneva which I understand from sources can not be increased in Geneva due to the size of the property. This is why integration is progressing at Daresbury. We know through previous RNS & analyst reports that adding additional CCL's is proven technology by CERN who are world leaders in linear accelerators. That is why reports all say the project has been somewhat de-risked.
There is always a risk and much fine tuning will be required, I sincerely hope it will be successful and as PM44 has highlighted the rewards will be very high. Hope this helps and GLA
Munners: 190 Mev would be suitable for most treatments...I would expect Daresbury to be at that level when approx 3 more CCL's are delivered and positioned. It would seem looking at the upcoming timelines this progress could be reported in the 4th quarter along with other milestones which would be good for price momentum.
https://www.avoplc.com/Portals/0/Documents/Investor%20Relations/General%20Meetings/AGM%20Presentation.pdf
Interesting comparisons with the UCL site, clearly LIGHT will be extremley disruptive technology.
The presentation inlcudes details of the Geneva sites, Daresbury site and more photos of Harley Street
Does anyone have any observations from the meeting?
Solow..you are correct looking at March 2017 Timeline, but this was revised in March 2018 and a great deal has progressed since then with new major shareholders and capital etc. Unless you are shorting this stock I believe in the scheme of things even if there are some delays this is a pretty good update!
I believe the linear technology has already been validated by CERN if you read all the Analyst reports going back at least to 2017. The hardest part was getting to 52Mev and thereafter it is down to integrating the CCL's which are similar structures as have been previously proven. To be fair to the company the Technical update today confirms thr Timeline as per presented in March 2018.is on track. I am somewhat relieved!!!
I would refer you to the Harman & Co report March 2018 (4th Qtr ) and March 2017 (3rd Qtr) Timeline. First patient was always H2 2020. With disruptive new technology I really dont think minor delays are to be concerned about and the company has always said H2 2020 as far as I have followed them.
Everything looks to be well organised and on track!
https://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/w93z4dw